2025-10-23 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided. The report is structured with key figures first, followed by a more detailed analysis.

## Johnson & Johnson (JNJ) Stock Analysis

**Ticker:** JNJ
**Company Overview:** Johnson & Johnson is a global healthcare company that develops, manufactures, and sells a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 47.76%
*   **VOO Cumulative Return:** 99.09%
*   **Absolute Divergence:** -48.33% (JNJ is lagging S&P 500)
*   **Relative Divergence:** 21.0 (Indicates JNJ's performance is in the lower range of its historical divergence from the S&P 500)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period analyzed. The relative divergence suggests this underperformance is not unusual compared to its historical patterns, but it's still a substantial difference.

**Alpha, Beta Analysis**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2015-2017  |   26   |  66.8 |    -2   |   -0.1 |    340.7 |
| 2016-2018  |   14   |  10.7 |    -1   |    0.1 |    314.7 |
| 2017-2019  |   20   |  71.5 |    -2   |    0.4 |    355.7 |
| 2018-2020  |   19   |  79.2 |    -4   |    0.4 |    383.8 |
| 2019-2021  |   33   |  79.2 |   -14   |    0.5 |    417.2 |
| 2020-2022  |    8   |  79.6 |     9   |    0.4 |    430.8 |
| 2021-2023  |  -19   |  79.6 |   -20   |    0.3 |    382.2 |
| 2022-2024  |  -32   |  79.6 |   -53   |    0.3 |    352.7 |
| 2023-2025  |   19   |  79.6 |   -45   |    0.1 |    467.9 |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate has fluctuated.
*   **MDD:** The Maximum Drawdown is relatively high across the board.
*   **Alpha:** The alpha is mostly negative, indicating underperformance relative to its benchmark, although there is a positive alpha in 2020-2022.
*   **Beta:** The beta is low.

### 2. Recent Stock Price Movement

*   **Current Price:** 191.88
*   **Last Market Data:** Price: 192.94, Previous Close: 191.88, Change: 0.55
*   **5-Day Moving Average:** 192.42
*   **20-Day Moving Average:** 187.72
*   **60-Day Moving Average:** 179.31

**Analysis:** The stock price is currently above its 20-day and 60-day moving averages, suggesting a short-term upward trend. The price slightly increased in the last market.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 77.22 (Overbought)
*   **PPO:** 0.0346
*   **Hybrid Signal:** Buy 100% of cash (5 shares - Very Safe - MRI:0.90), Monthly invest 0.8% of total investment ($1,000.00)
*   **Recent (20-Day) Relative Divergence Change:** -1.7 (Short-term decrease)
*   **Expected Return (vs. S&P 500):** -78.1% (Long-term underperformance)

**Analysis:**
*   **MRI and Hybrid Signal:** The MRI suggests a high level of investment safety, and the hybrid signal recommends investing.
*   **RSI:** The RSI indicates that the stock is currently overbought.
*   **Divergence Change:** Indicates a short-term decrease.
*   **Expected Return:** The significantly negative expected return suggests caution.

### 4. Recent News & Significant Events

*   **Conference Participation:** Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference.
*   **Analyst Sentiment:** News articles suggest a shifting narrative around J&J with recent results and analyst upgrades.
*   **Investor Attention:** JNJ is attracting investor attention.
*   **Personnel Changes:** Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales.

**Analysis:** The news suggests positive analyst sentiment and growing investor interest in J&J.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.08)
*   **Target Price:** Average: 198.47, High: 225.00, Low: 155.00

**Analysis:** The analyst consensus is "Buy" with a target price significantly higher than the current price.

### 5. Recent Earnings Analysis

| Date       |    EPS | Revenue    |
|:-----------|-------:|:-----------|
| 2025-10-22 |   2.14 | 23.99 B$   |
| 2025-07-24 |   2.3  | 23.74 B$   |
| 2025-04-23 |   4.57 | 21.89 B$   |
| 2024-10-23 |   1.12 | 22.47 B$   |
| 2025-10-22 |   1.12 | 22.47 B$   |

**Analysis:**
Revenue: The company's revenues shows growth.
EPS: EPS fluctuates with a high in Q1 2025.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin   |
|:-------------|:----------|:----------------|
| 2025-06-30   | $23.74B   | 67.87%          |
| 2025-03-31   | $21.89B   | 66.40%          |
| 2024-12-31   | $22.52B   | 68.35%          |
| 2024-09-30   | $22.47B   | 69.01%          |
| 2024-06-30   | $22.45B   | 69.40%          |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|:-------------|:----------|:-------|
| 2025-06-30   | $78.47B   | 7.06%  |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80%  |
| 2024-09-30   | $70.16B   | 3.84%  |
| 2024-06-30   | $71.54B   | 6.55%  |

**Analysis:**
*   **Revenue:** Shows a gradual increase over the quarters.
*   **Profit Margin:** Consistently high, indicating strong profitability.
*   **Equity:** Increasing trend in equity.
*   **ROE:** Fluctuates, with a notable spike in Q1 2025.

### 7. 종합적인 분석 (Overall Analysis)

Based on the provided data, here's a summary:

*   **Underperformance:** JNJ has underperformed the S&P 500 significantly.
*   **Positive Indicators:**
    *   Recent news and analyst upgrades suggest a positive shift in sentiment.
    *   Analyst consensus is "Buy" with a target price above the current price.
    *   Revenues is growing.
    *   High profit margins and increasing equity indicate financial strength.
*   **Mixed Indicators:**
    *   The RSI indicates that the stock is currently overbought.
    *   While the MRI suggests a high level of investment safety, the expected return is significantly negative.

**Conclusion:**

The analysis presents a mixed picture. While JNJ exhibits financial strength and is receiving positive attention from analysts, it has significantly underperformed the broader market. This suggests that while the company might be a relatively safe investment, it may not offer substantial growth potential in the near future. Investors should weigh the potential for future growth against the safety and stability of the company.
